3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Status
Recruiting
3
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
2
Breast
1
Conditions
Pancreatic Neoplasms
18
Carcinoma, Non-Small-Cell Lung
17
Urinary Bladder Neoplasms
14
Lung Neoplasms
11
Ovarian Neoplasms
10
Nasopharyngeal Carcinoma
9
Neoplasm Metastasis
8
Lymphoma, Large B-Cell, Diffuse
6
Cholangiocarcinoma
6
Biliary Tract Neoplasms
6
Non-Muscle Invasive Bladder Neoplasms
5
Breast Neoplasms
5
Triple Negative Breast Neoplasms
4
Fallopian Tube Neoplasms
4
Endometrial Neoplasms
4
Carcinoma, Transitional Cell
4
Recurrence
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Neoplasms
3
Lymphoma, Non-Hodgkin
3
Colorectal Neoplasms
3
Uterine Cervical Neoplasms
2
Urologic Neoplasms
2
Sarcoma
2
Rectal Neoplasms
2
Osteosarcoma
2
Melanoma
2
Lymphoma, Follicular
2
Lymphoma, B-Cell
2
Leiomyosarcoma
2
Interventions
pembrolizumab
31
Paclitaxel
14
Carboplatin
12
Cisplatin
8
lenvatinib
7
Pemetrexed
5
olaparib
4
belzutifan
4
Oxaliplatin
4
Fluorouracil
4
Docetaxel
4
Capecitabine
4
patritumab deruxtecan
3
Leucovorin
3
Gemcitabine
3
Bevacizumab
3
Albumin-Bound Paclitaxel
3
Acetaminophen
3
Saline Solution
2
Levoleucovorin
2
Irinotecan
2
Histamine H2 Antagonists
2
Histamine Antagonists
2
Etoposide
2
Dexamethasone
2
Cetuximab
2
130-nm albumin-bound paclitaxel
2
zanidatamab
1
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Gemcitabine
×
30 days
×
Clear all
NCT06788912
2026-05-26
MK-3475-01E
Merck Sharp & Dohme LLC
Phase 2
Recruiting
60 enrolled
NCT06841354
2026-05-22
TroFuse-011
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,000 enrolled
NCT06623422
2026-05-15
INTerpath-009
Merck Sharp & Dohme LLC
Phase 3
Recruiting
680 enrolled